Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias

Blood Transfusion

Volumn 11, Issue 1, 2013, Pages 108-122

  Viprakasit, Vip ^a   Gattermann, Norbert ^b   Lee, JongWook ^c   Porter, John B ^d   Taher, Ali T ^e   Habr, Dany ^f   Martin, Nicolas ^f   Domokos, Gabor ^f   Cappellini, MariaDomenica ^g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c The Catholic University of Korea   (South Korea)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

Chelation practice; Iron overload; Transfusion practice

Indexed keywords

FERRITIN; IRON;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL PRACTICE; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; GEOGRAPHY; HEALTH CARE COST; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE EAST; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE;

ADOLESCENT; ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; GUIDELINE ADHERENCE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED;

EID: 84872228814     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0012-12     Document Type: Article

References (31)

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5-11. (Pubitemid 28304491)
2. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353: 2769-78. (Pubitemid 43016816)
3. Hellström-Lindberg E. Management of anemia associated with myelodysplastic syndrome. Semin Hematol 2005; 42: S10-S13. (Pubitemid 40410478)
4. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-73. (Pubitemid 24265698)
5. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 2007; 82: 255-65. (Pubitemid 46564319)
6. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93: 741-52. (Pubitemid 351669315)
7. Arrizabalaga B, del Cañizo C, Remacha A, et al. Guía clínica de quelación del paciente con síndrome mielodisplásico [Clinical guide to chelation therapy for patients with myelodysplastic syndrome (Spanish Guidelines)]. Haematologica 2008; 93 (Suppl 1): 3-10.
8. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858-61.
9. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology v.2: Myelodysplastic Syndromes. 2010. Available at: http://www.nccn.org/professionals/physician-gls/pdf/mds.pdf. Accessed on 25/01/2012.
11. Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK. 2008. Available at: http://www.sicklecellsociety. org/app/webroot/files/files/CareBook.pdf. Accessed on 25/01/2012.
12. Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. Avaliable at http://www thalassaemia org cy/pdf/Guidelines-2nd-revised-edition-EN pdf 2008. Accessed on 25/01/2012.
13. Vichinsky E, Levine L. Standards of Care Guidelines for Thalassemia. 2008. Children's Hospital & Research Center Oakland.
14. National Institutes of Health NHLBI. The management of sickle cell disease. NIH Publication No 02-2117. 2002. Available at: http://www.nhlbi.nih. gov/health/prof/blood/sickle/sc-mngt.pdf. Accessed on 25/01/2012.
15. Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusiondependent anemias. Haematologica 2010; 95: 557-66.
16. St Pierre TG, Clark PR, Chua-anusorn W. Single spinecho proton transverse relaxometry of iron-loaded liver. NMR Biomed 2004; 17: 446-58. (Pubitemid 39549422)
17. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003; 102: 2670-7. (Pubitemid 37193611)
18. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-87. (Pubitemid 40298370)
19. Lee J-W, Yoon S-S, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116: 2448-54.
20. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous â-thalassemia. N Engl J Med 1994; 331: 574-8. (Pubitemid 24265699)
21. Abetz L, Baladi J-F, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006; 4: 73.
22. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.
23. Gattermann N, Porter J, Lopes LF, Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am 2005; 19 (Suppl 1): 18-25.
24. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82: 458-65.
25. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a oncedaily oral iron chelator, in heavily iron-overloaded patients with â-thalassaemia. Eur J Haematol 2009; 82: 454-7.
26. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with â-thalassemia. Blood 2006; 107: 3455-62.
27. Riewpaiboon A, Nuchprayoon I, Torcharus K, et al. Economic burden of beta-thalassemia/Hb E and betathalassemia major in Thai children. BMC Research Notes 2010; 3: 29.
28. Viprakasit V, Chan LL, Chong QT, et al. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009; 90: 435-45.
29. Storb R. Aplastic anemia. J Intraven Nurs 1997; 20: 317-22. (Pubitemid 27511930)
30. Lee JW. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol 2008; 88: 16-23.
31. Suzuki T, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol 2008; 88: 30-5.